Towards the application of Tc toxins as a universal protein translocation system

Daniel Roderer¹, Evelyn Schubert¹, Oleg Sitsel¹ & Stefan Raunser¹*

Tc toxins are bacterial protein complexes that inject cytotoxic enzymes into target cells using a syringe-like mechanism. Tc toxins are composed of a membrane translocator and a cocoon that encapsulates a toxic enzyme. The toxic enzyme varies between Tc toxins from different species and is not conserved. Here, we investigate whether the toxic enzyme can be replaced by other small proteins of different origin and properties, namely Cdc42, herpes simplex virus ICP47, Arabidopsis thaliana iLOV, Escherichia coli DHFR, Ras-binding domain of CRAF kinase, and TEV protease. Using a combination of electron microscopy, X-ray crystallography and in vitro translocation assays, we demonstrate that it is possible to turn Tc toxins into customizable molecular syringes for delivering proteins of interest across membranes. We also infer the guidelines that protein cargos must obey in terms of size, charge, and fold in order to apply Tc toxins as a universal protein translocation system.
Bacteria produce numerous pore-forming toxins that function by puncturing the plasma membrane of target cells. There, they either form a perforating pore that dissipates crucial electrochemical gradients or function as an injection device that translocates a toxic molecule into the cytoplasm. Tripartite toxin complexes (Tc) belong to the latter class and are widespread in insect and human pathogens1,2. Originally discovered in the insect pathogen *Photorhabdus luminescens*, many gene loci encoding these proteins have since been found in other organisms. Tc toxins appear to be particularly well represented in enterobacteria, with examples being the insect pathogen *Xenorhabdus nematophila*4,5, the facultative human pathogen *Photorhabdus asymbiotica*6, and the deadly human and insect pathogens *Yersinia* spp7,8.

Tc toxins consist of three components: TcA, TcB, and TcC. The ~1.4 MDa TcA is a homopentameric bell-shaped molecule that mediates target cell association, membrane penetration, and toxin translocation9. TcA consists of a central, pre-formed α-helical channel connected to an enclosing outer shell by a linker that acts as an entropic spring during toxin injection10,11. The shell is composed of a structurally conserved α-helical domain that is decorated by a neuraminidase-like domain, as well as by variable immunoglobulin-fold receptor-binding domains. In some Tc toxins, the latter are functionally replaced by small soluble proteins that form a quaternary complex with the TcA subunit12,13.

TcB and TcC together form a ~250 kDa cocoon that encapsulates the autoproteolytically cleaved ~30 kDa C-terminal hypervariable region (HVR) of TcC, the actual cytotoxic component of the Tc toxin10,14. The HVR resides in a partially or completely unfolded state in the cocoon10,15. Binding of TcB-TcC to TcA and the subsequent pH-dependent prepore-to-pore transition of the ABC holotoxin result in a continuous translocation channel from the TcB-TcC lumen across the target cell membrane into the cytoplasm that allows the translocation of the HVR16.

Previously, we resolved several crucial steps of the Tc intoxication mechanism17. The first of these is holotoxin formation, where the key feature is a conformational transition of the TcB domain that binds to TcA. This domain is a six-bladed β-propeller, and upon contact of TcA with TcB, the closed blades of the β-propeller unfold and refold in an open form. Consequently, the HVR passes through the β-propeller and enters the translocation channel16. The assembled holotoxin binds to receptors on the target cell surface and is endocytosed10,18. Upon acidification of the late endosome, the bottom of the TcA shell opens and the prepore-to-pore transition of the Tc toxin occurs9. During this process, the compaction of the stretched linker between the shell and the channel drives the channel through the now open bottom of the shell and across the membrane11. The α-helical domain of the outer shell, which possesses a stabilizing protein knot, functions as a stator for the transition19. Subsequently, the tip of the channel opens and the HVR is translocated into the target cell cytoplasm, where it interferes with critical cellular processes, ultimately causing cell death18.

Two HVRs from *Photorhabdus luminescens* TcC proteins have been found to function as ADP-ribose transferases targeting actin (TccC3HVR) and Rho GTPases such as RhoA and Cdc42 (TccC5HVR)18. However, no HVR structures have been solved so far, limiting our understanding of the structural requirements for proteins translocated by Tc toxins. Although previous studies on other bacterial ADP-ribose transferases have shown that these enzymes can in fact be structurally similar even without any significant sequence similarity20–23, we do not know if this also holds true for Tc toxin HVRs.

In this study, we raise an interesting question related to this topic: can the sophisticated Tc toxin translocation system be hijacked and used to transport proteins other than the natural HVRs? Such a proof of concept has already been demonstrated for the anthrax toxin, which was used to transport proteins fused to anthrax lethal factor into cells, including the TccC3HVR of Tc toxins19. In fact, similar designs based on the diphtheria toxin and *Pseudomonas aeruginosa* exotoxin A have already been explored as anticancer drugs25,26. These systems however have the disadvantage that the fused cargo is exposed to the external environment in the cocoon, potentially causing the cargo to show premature and unspecific activity and limiting the usefulness of such constructs for both medical and research applications. This drawback could be avoided if the cargo were to be transported to its destination in an inactive form inside the TcB-TcC cocoon, and only activated after protein translocation through the TcA pentamer.

To achieve this, the cargo protein to be translocated would have to be fused to the C-terminus of TcC instead of the native HVR in order to get encapsulated in the cocoon and subsequently translocated through TcA into the target cell (Fig. 1a, b). We explore these aspects here by swapping the TccC3HVR to comparably sized proteins with diverse origins and functions (Supplementary Figure 1a), and then assess holotoxin formation and cargo translocation of these constructs. We find that stable ABC holotoxin is formed for cargos below a total size of ~20 kDa, which is in accordance with our previous finding that an empty TcB-TcC cocoon does not form ABC with high-affinity either16. We then screen different cargos for their translocation after triggering the prepore-to-pore transition in vitro. Several, but not all small proteins are successfully translocated when fused with parts of TccC3HVR. Generally, the non-translocated cargos have a considerably lower isoelectric point (pI) than the translocated constructs. Furthermore, the crystal structures of two non-translocated constructs show us that the formation of structural elements inside the TcB-TcC cocoon, in particular those that interact stably with the inner surface of the cocoon, also prevent cargo translocation.

Together, our results show that cargo proteins must fulfill three prerequisites to be successfully translocated by TcA. The first is the cargo size, which needs to be above a threshold of ~20 kDa to form a stable holotoxin complex. The second is the net charge, which must be positive at neutral pH values. The third is that the cargo must not form structural elements within TcB-TcC. Observing these guidelines is the key to creating functional Tc-based protein injection devices.

**Results**

**TcC-HVRs are exchangeable in Tc toxins.** As an initial proof that different cargos fused to TcC can be translocated, we tested whether HVRs from different TcC proteins are exchangeable and result in functional, toxic ABC complexes. For this, we replaced the TccC3HVR sequence after the autoproteolytic cleavage site in TcdB2-TccC3 to that of TccC5HVR, resulting in the chimeric TcdB2-TccC3-TccC5HVR complex. After assembly of the ABC-TccC5HVR holotoxin, we assessed cytotoxicity on Hek293T cells. Complete cell death occurs upon addition of 2 nM ABC-TccC5HVR toxin, compared with cell death at 0.5 nM when exposed to the ABC-TccC3HVR holotoxin (Fig. 1c). This is in accordance with previous findings that the cytotoxic effect of TccC5HVR is less pronounced than that of TccC3HVR18. This experiment shows that the cocoon formed by TcdB2-TccC3 is capable of also encapsulating and translocating other HVRs, such as TccC5HVR. We therefore chose TcdB2-TccC3 to function as a cocaine scaffold for translocation of other cargo proteins, which are not components of the Tc toxin system. Importantly, the two different HVRs do not show any pronounced sections of sequence
identity (Supplementary Fig. 1b), indicating that there is no conserved motif in Tcc-HVRs that is a general prerequisite for successful translocation.

Replacement of TcC HVR by heterologous cargo proteins. Our next step was to replace the HVR of TccC with unrelated heterologous proteins and test the capability of the holotoxin to translocate these. The criteria used to select replacement proteins were (i) a small size (11–34 kDa) to guarantee that they fit into the TcB-TcC cocoon, (ii) diverse folds to assess whether this influences the translocation capability, (iii) different oligomeric arrangements to see if this affects proper cocoon assembly, and (iv) various organismal origins to further reduce bias. The proteins selected according to these criteria were the small GTPase cell division control protein 42 homolog (Cdc42) from Homo sapiens, herpesviral infected cell protein 47 (ICP47), the light/oxygen/voltage-sensing domain of the Arabidopsis thaliana blue light receptor (iLOV), the multi-ligand binding enzyme dihydrofolate reductase from Escherichia coli (DHFR), the Ras-binding domain of CRAF kinase from Homo sapiens (RBD), and tobacco etch virus (TEV) protease. Several of these proteins possess interesting properties that were hypothesized to provide additional information on requirements for translocation: Cdc42 is a homodimer in solution, ICP47 is intrinsically disordered, iLOV has a flavin mononucleotide chromophore, and TEV contains two β-barrels, which represent stable folds (Supplementary Fig. 1a).

Interestingly, all tested chimeric cocoons could be well expressed in E. coli and purified. We then mixed the cocoons with TcA and assessed holotoxin formation by negative stain EM after size exclusion chromatography (SEC). In case of the wild-type TccC3HVR, the affinity of TcB-TcC to TcA is in the picomolar range, resulting in almost complete holotoxin formation. This was also the case for holotoxins composed of TcA and cocoons containing Cdc42 (20.3 kDa) and TEV (28.1 kDa) (Fig. 2a, b, Supplementary Fig. 2a). This demonstrates that TcB-TcC complexes with non-native cargos are able to form holotoxin complexes. In contrast, holotoxin formation was tremendously reduced when cocoons with ICP47 (13.2 kDa), iLOV (13.2 kDa), and DHFR (18.4 kDa) as cargos were used, indicating that there is a size limit for the cargo (Fig. 2b, Supplementary Fig. 2a). Previously, we demonstrated that the HVR inside the cocoon has an influence on the gatekeeper domain of the β-propeller and an empty cocoon has a much lower affinity to TcA than the wild-type. We have proposed that this might be caused by steric...
pressure applied by the HVR and consequently no or a small HVR would result in reduced complex formation. Our results with the different cargos support this hypothesis and indicate that the minimal size requirement for the cargo is around 20 kDa in order to guarantee high-affinity holotoxin assembly.

**The size of the cargo determines holotoxin formation.**

To further explore the influence of cargo size on holotoxin formation, we created a truncated version of the native TccC3HVR (residues 1–132) and increased the size of the shorter cargos by adding differently sized parts of TccC3HVR to the N- or C-termini (see Methods for details). To achieve this, we introduced an EcoRI restriction site in frame after the first 138 or 384 base pairs (bp) of the sequence coding for the HVR, resulting in two possible N-terminal extensions of the cargo proteins with 45 or 128 residues from the original HVR, respectively. In addition, we introduced a NotI restriction site 150 bp upstream of the stop codon, resulting in a C-terminal extension of the cargo with the C-terminal 50 residues of the HVR. Altogether, five different combinations of extensions of the cargos were possible: HVR45-cargo, HVR128-cargo, HVR45-cargo-HVR50, HVR128-cargo-HVR50, and cargo-HVR50.

As ICP47 has almost no secondary structure that could influence the size dependency (Supplementary Fig. 1a), it was a particularly compelling test case. Similarly to the cocoon with only ICP47 (11.3 kDa), cocoons containing the chimeras ICP47-HVR50 (17.1 kDa) or HVR45-ICP47-HVR50 (21.6 kDa) did not have a high affinity to TcA. The same was true for HVR45-RBD (14.2 kDa). However, the longer constructs, namely HVR128-RBD (22.4 kDa), HVR128-ICP47 (24.5 kDa) and HVR128-ICP47-HVR50 (30.3 kDa), resulted in high-affinity holotoxin formation (Fig. 2a–c). Increasing the size of iLOV (HVR128-iLOV (26.4 kDa)) and DHFR (HVR128-DHFR (31.6 kDa)) had the same effect (Supplementary Fig. 2a).

In all chimeras that led to high-affinity holotoxin assembly, the cargo was fused to HVR128. Therefore, one might ask whether these first 128 residues of Tcc3HVR contain a motif important for activating TcB-TcC, which the holotoxin-forming Cdc42 and TEV constructs coincidentally possess. However, since HVR (1–128) alone does not activate the cocoon, as can be seen with the HVR (1–132) truncation construct (13.8 kDa) of Tcc3HVR (Supplementary Fig. 2b), we believe that the presence of HVR128 is not a prerequisite for the activation mechanism. Taken together, these results confirm our hypothesis that the cargo has to have a certain size (at least ~20 kDa) in order to activate the cocoon and put it into an assembly-competent state. At the same time the variety of assembly-competent constructs suggests that the nature of the cargo is not important for this activation.
mechanism, supporting the idea that a general high sterical ‘pressure’ is sufficient.

Translocation of cargo proteins by TcA. Having demonstrated that holotoxins containing heterologous cargos can be assembled, our next step towards using the Tc scaffold as a customized protein injection system was to show that the cargo can be successfully translocated. To assess the translocation of different cargo proteins in vitro and activation of TccC3HVR, we first assessed the release of TccC3HVR. Western blots show that the constructs migrate at higher retention volumes during size exclusion chromatography in comparison with pH 8-incubated controls. This corresponds to translocation and release of the cargo proteins from the holotoxin, as illustrated schematically in Supplementary Fig. 3. b ADP-ribosylation of F-actin by translocated TccC3HVR in comparison with recombinantly purified TccC3HVR. Western blots show the increasing appearance of ADP-ribosylated actin dependent on the TccC3HVR concentration for both preparations. c No translocation was observed for Cdc42 and TEV protease cargo alone, or DHFR and Cdc42 fused to the N- or C-terminus of TccC3HVR. Western blots show the presence of the constructs at lower retention volumes during size exclusion chromatography both at pH 8 and pH 11, meaning they co-localize with the rest of the holotoxin even after prepore-to-pore transition and are not translocated. Uncropped images of the Western blots in panels a–c are provided as a Source Data file.

Fig. 3 Translocation of various non-natural cargos in vitro and activation of TccC3HVR. a Successful translocation of ICP47, RBD, and iLOV fused to the N- or C-terminus of TccC3HVR. After incubation at pH 11, which causes the toxin to undergo prepore-to-pore transition, Western blots show that these constructs migrate at higher retention volumes during size exclusion chromatography in comparison with pH 8-incubated controls. This corresponds to translocation and release of the cargo proteins from the holotoxin, as illustrated schematically in Supplementary Fig. 3. b ADP-ribosylation of F-actin by translocated TccC3HVR in comparison with recombinantly purified TccC3HVR. Western blots show the increasing appearance of ADP-ribosylated actin dependent on the TccC3HVR concentration for both preparations. c No translocation was observed for Cdc42 and TEV protease cargo alone, or DHFR and Cdc42 fused to the N- or C-terminus of TccC3HVR. Western blots show the presence of the constructs at lower retention volumes during size exclusion chromatography both at pH 8 and pH 11, meaning they co-localize with the rest of the holotoxin even after prepore-to-pore transition and are not translocated. Uncropped images of the Western blots in panels a–c are provided as a Source Data file.

Translocation of cargo proteins by TcA. Having demonstrated that holotoxins containing heterologous cargos can be assembled, our next step towards using the Tc scaffold as a customized protein injection system was to show that the cargo can be successfully translocated. To assess the translocation of different cargo proteins without having to rely on protein-specific enzymatic activity readouts, we developed a cell-free in vitro translocation assay. First, the prepore-to-pore transition of ABC is triggered by shifting the pH to 11. If the cargo can be translocated, it will be ejected through the TcA translocation channel and dissociate from the holotoxin, as described for wild-type ABC (ABC(WT))atures. Successfully translocated 20–30 kDa cargos can then be easily separated from the 1.7 MDa ABC injection machinery by SEC (Supplementary Fig. 3a), whereas non-translocated cargos will still be holotoxin-associated and therefore co-migrate with the 1.7 MDa peak (Supplementary Fig. 3b). As proof of principle, we first assessed the release of TccC3HVR in ABC(WT) before moving on to test the heterologous cargos. Indeed, after 48 h of incubation at pH 11, a substantial fraction of TccC3HVR migrates much later than the ABC peak (Fig. 3a), indicating that it has been successfully released and translocated through TcA.

To test whether the TccC3HVR folds and adopts an active conformation after in vitro translocation, we compared the activity of the translocated ADP-ribosyltransferase with that of recombinantly purified TccC3HVR, using an actin-ribosylating assay (Methods). Although the activity of the translocated ADP-ribosyltransferase was about half of that of the recombinantly purified enzyme, it clearly ADP-ribosylated F-actin (Fig. 3b). This demonstrates that most of the translocated ADP-ribosyltransferase was folded to its active form after translocation. Importantly, this in vitro assay shows that folding and activity of the ADP-ribosyltransferase do not require additional cofactors such as chaperones and we believe that this is also the case for other translocated cargos.

Next, we tested whether the various cargo proteins could be translocated. We first assessed Cdc42 and TEV, which do not need to be fused to TccC3HVR fragments in order to form a holotoxin. However, the proteins were not translocated by TcA.
To determine whether fusing sequences from TccC3HVR can restore translocation competence, we extended Cdc42 with either the C-terminus of TccC3HVR or with both of its termini. However, these cargos could also not be translocated by TcA (Fig. 3c), indicating that neither the C-terminus nor both termini of the HVR are sufficient to enable translocation.

However, the four other cargos that facilitated holotoxin formation only when fused to fragments of TccC3HVR were successfully translocated, namely HVR128-ICP47-HVR50, HVR128-ICP47, HVR128-iLOV, and HVR128-RBD (Fig. 3a). As the C-terminal region that is translocated first in ABC(WT)16 differs considerably between these cargos, we conclude that there is no specific sequence at the C-terminus that determines whether a cargo is translocated or not. In the case of HVR128-iLOV, iLOV did not produce fluorescence in the cocoon, whereas TcB-TcC-iLOV showed that iLOV without the extension is able to fold inside the cocoon and has access to the cofactor FMN.

In contrast to the other three HVR128-containing cargos, DHFR is not translocated when fused to the same HVR128 N-terminus (Fig. 3c). Together with the non-translocated HVR45-Cdc42-HVR50 cargo, this shows that the sequence of the N-terminus is also not the determinant of cargo transport through TcA. Therefore, there must be another factor at work that establishes translocation competence.

A comparison of the four translocated fusion proteins (HVR128-ICP47, HVR128-ICP47-HVR50, HVR128-RBD, and HVR128-iLOV) and the native cargos Tcc3HVR and Tcc5HVR shows that their common feature is a positive net charge at neutral pH, with isoelectric points of at least 7.9 (Fig. 3a). In the case of the fusion constructs, this is mainly due to the highly positively charged HVR128 (pI 9.75), which is larger than the cargo protein in all cases (maximum size 13.2 kDa). We therefore conclude that besides being large enough, the cargo has to be positively charged (pI ≥ 8) in order to be translocated.

In line with this, the six constructs that formed holotoxin complexes but did not show translocation had mostly negatively charged cargos (Fig. 4). Only two non-translocated cargos, namely HVR45-Cdc42-HVR50 and TEV were positively charged. The TEV construct we used has a highly positively charged penta-arginine tail to allow purification by cation exchange chromatography without changing its activity37, a modification that raises the pl of TEV from 8.67 to 9.62. Although such a change in pI should favor translocation, it is possible that distributing the positive charges in such an uneven manner rather hinders it.

TEV protease is not an exceptionally stable protein, as it unfolds at ~52 °C38. However, it contains two small β-barrels (Supplementary Fig. 1a), which are known to be a notoriously stable fold34. Therefore, we believe that these domains are more rigid than the native Tcc3HVR or other translocated cargos such as HVR128-iLOV, which might prevent the protein from being translocated. To prove this, we determined the structure of TcB-TcC-TEV to a resolution of 3.7 Å using X-ray crystallography (Supplementary Table 1). The cocoon of TcB-TcC-TEV shows an identical size and shape to the TcB-TcC(WT) cocoon10, with a Cα RMSD of 0.552 Å2. However, the electron density inside appears already at a higher sigma level, indicating that the encapsulated TEV is indeed more rigid and ordered than the native Tcc3HVR (Supplementary Fig. 3c). This is the likely cause for TEV not being translocated. As folded proteins do not fit through the narrow constriction site of the translocation channel16, the formation of defined structural elements such as β-barrels in the cocoon probably results in translocation arrest.

### Table 1

| Cargo          | Size (kDa) | High-affinity ABC formation | pl   | Translocation |
|----------------|------------|-----------------------------|------|---------------|
| TccC3HVR       | 30.4       | yes                         | 9.68 | Yes           |
| Tcc5HVR        | 30.3       | yes                         | 7.90*| Yes, in vivo**|
| ICP47          | 11.3       | no                          | 5.64 | n.a.          |
| ICP47-HVR50    | 17.1       | no                          | 8.09 | n.a.          |
| HVR128-ICP47   | 21.6       | no                          | 9.73 | n.a.          |
| HVR128-ICP47-HVR50 | 30.3 | yes                         | 9.62 | Yes           |
| HVR45-RBD      | 14.2       | no                          | 10.06| n.a.          |
| HVR128-RBD     | 22.4       | no                          | 9.73 | Yes           |
| iLOV           | 13.2       | no                          | 5.13 | n.a.          |
| HVR128-iLOV    | 26.4       | yes                         | 8.73 | Yes           |
| DHFR           | 18.4       | no                          | 4.77 | n.a.          |
| HVR128-DHFR    | 31.6       | yes                         | 5.74 | no            |
| Cdc42          | 20.3       | no                          | 5.11 | n.a.          |
| Cdc42-HVR50    | 26.1       | yes                         | 6.44 | no            |
| HVR45-Cdc42-HVR50 | 30.6 | yes                         | 8.69 | no            |
| Cdc42(1-164)-HVR50 | 24.9 | yes                         | 6.90 | no            |
| TEV            | 28.1       | yes                         | 9.48 | no            |

**Interaction with cocoon inhibits translocation of Cdc42.** Although Cdc42 does not possess any folds that are immediately classifiable as very stable, we examined the Cdc42 constructs in more detail and solved the crystal structure of TcB-TcC-Cdc42 to 2.0 Å to find out whether Cdc42 folding inside the cocoon is nonetheless a plausible explanation for its translocation incompetence (Fig. 5a, Supplementary Table 1).

The overall shape of the TcB-TcC-Cdc42 cocoon is identical to wild-type (TcB-TcC(WT)) and empty TcB-TcC10, with Cα RMSD values of 0.424 Å2 and 0.414 Å2 between TcB-TcC-Cdc42/TcB-TcC(WT) and TcB-TcC-Cdc42/empty TcB-TcC, respectively, indicating that a different cargo does not influence the RHS repeat structure of the cocoon. Similarly to Tcc3HVR in the TcB-TcC (WT) cocoon, Cdc42 is not structured inside the cocoon. However, we found an ordered electron density in close spatial proximity to the β-propeller domain, which corresponds to an α-helix not present in other TcB-TcC structures obtained so far. The high-resolution of the map and availability of the Cdc42 structure27 enabled us to identify the α-helix inside the cocoon as the C-terminus of Cdc42 (N167–P179) (Supplementary Fig. 4a, b).

Importantly, the helix is attached to the TcB protein in an orientation perpendicular to that expected from natural translocation (Fig. 5a, b), and its amphipathic nature facilitates interaction with a hydrophobic pocket on the inner surface of the cocoon (Fig. 5c). The side chains of F169, I173, L177, and P179 are rigidly oriented toward the hydrophobic cleft, where they are in close contact with L39, L41, P42, L366, L368, M702, N704, V708, H710, L1203, and F1349 of the cocoon (Fig. 5d). In contrast, D170, E171, and E178 face the TcB-TcC lumen with more degrees of freedom. This is reflected in the quality of the crystallographic density, with only the residues pointing toward the cocoon surface being well resolved (Supplementary Fig. 4c).

### Table 2

| Cargo          | Size (kDa) | High-affinity ABC formation | pl   | Translocation |
|----------------|------------|-----------------------------|------|---------------|
| TccC3HVR       | 30.4       | yes                         | 9.68 | Yes           |
| Tcc5HVR        | 30.3       | yes                         | 7.90*| Yes, in vivo**|
| ICP47          | 11.3       | no                          | 5.64 | n.a.          |
| ICP47-HVR50    | 17.1       | no                          | 8.09 | n.a.          |
| HVR45-ICP47    | 21.6       | no                          | 9.73 | n.a.          |
| HVR45-RBD      | 14.2       | no                          | 10.06| n.a.          |
| HVR128-RBD     | 22.4       | no                          | 9.73 | Yes           |
| iLOV           | 13.2       | no                          | 5.13 | n.a.          |
| HVR128-iLOV    | 26.4       | yes                         | 8.73 | Yes           |
| DHFR           | 18.4       | no                          | 4.77 | n.a.          |
| HVR128-DHFR    | 31.6       | yes                         | 5.74 | no            |
| Cdc42          | 20.3       | no                          | 5.11 | n.a.          |
| Cdc42-HVR50    | 26.1       | yes                         | 6.44 | no            |
| HVR45-Cdc42-HVR50 | 30.6 | yes                         | 8.69 | no            |
| Cdc42(1-164)-HVR50 | 24.9 | yes                         | 6.90 | no            |
| TEV            | 28.1       | yes                         | 9.48 | no            |
Interestingly, the affinity of the Cdc42 α-helix for this part of the cocoon is strong enough to displace the N-terminus of TcB, which resides at this position in TcB-TcC(WT) (Supplementary Fig. 4d). The N-terminus of TcB-TcC-Cdc42 is correspondingly not resolved, indicating that it protrudes into the cocoon lumen. The tight attachment of Cdc42 via its C-terminus in close spatial proximity to the TcB gatekeeper domain could help this construct to form a holotoxin with high affinity comparable to the constructs with larger cargos, despite Cdc42 being at the lower limit of the cargo size prerequisite (Fig. 2, Supplementary Fig. 2).

The stable nature of the Cdc42 α-helix interaction with the cocoon raises the question of whether it remains bound even after holotoxin formation, in which case it would not be able to enter the translocation channel. We addressed this issue by determining the 5 Å structure of the ABC-Cdc42 holotoxin using cryo-EM (Supplementary Fig. 5). Indeed, a small helix-shaped density appears at the interaction site even at a comparably high-map binarization threshold, despite the limited resolution of the 3D reconstruction. Fitting the entire crystal structure of TcB-TcC-Cdc42 into the cryo-EM density map results in a very good match of the Cdc42 α-helix with the additional map density of ABC-Cdc42 (Fig. 5e). In contrast, no comparable cryo-EM density is present at the same position in ABC(WT) (Fig. 5f). There is however a stretch of Cdc42 density that protrudes into the β-propeller domain of TcA but does not continue further into the channel. This indicates that although Cdc42 cannot be translocated, it applies a steric pressure on the...
TcB gatekeeper domain, resulting in the high-affinity binding of TcB to TcA.

These results demonstrate that if the encapsulated cargo forms stable structural elements that strongly interact with the inner lumen of the cocoon, the cargo cannot be translocated by TcA even if it is positively charged and large enough.

**Discussion**

Taken together, our results indicate that the *P. luminescens* Tc toxin can be successfully transformed into a universal protein translocation system as long as the cargo protein fulfills several prerequisites. The first of these is cargo size. While its upper limit is defined by the size of the cocoon, an exact value was not determined in this study. The largest cargo tested here was HVR128-DHFR (31.6 kDa), which is 1.2 kDa larger than the TccC3HVR natural cargo (Fig. 4). At the same time, the largest natural cargo of a *P. luminescens* Tc toxin is TccC1HVR at 35.1 kDa, providing a potential upper size limit and meaning that larger ADP-ribosyltransferases like the 49.4 kDa C2 toxin of *Clostridium botulinum* would likely not fit into the cocoon. It remains to be explored whether the cocoon itself can be enlarged by adding further RHS repeats, thereby expanding the upper cargo size limit.

Importantly, we discovered that the lower size limit of the cargo is in the 20–22 kDa range, and the ability to form the ABC holotoxin is drastically reduced if the cargo size is below this limit (Fig. 4, Fig. 6). This finding echoes previous results showing that a comparable decrease in affinity between empty TcB-TcC and TcA occurs because there is no HVR present to apply steric pressure on the TcB gatekeeper domain that is essential for binding to TcA. Similarly, small cargos will likely be too mobile inside the cocoon to cause gatekeeper destabilization. The lower size limit is slightly flexible, e.g. Cdc42 (20.3 kDa) forms holotoxin whereas HVR45-Icp47-HVR50 (21.6 kDa) does not (Fig. 4). This is potentially caused by the C-terminal helix of Cdc42 attaching the rest of the cargo to the vicinity of the cocoon exit, allowing the Cdc42 N-terminus to destabilize the gatekeeper more easily, which results in holotoxin formation but also prevents subsequent cargo transport. We therefore hypothesize that translocation will likely be impaired if a TcB-TcC cocoon loaded with a small cargo binds with high affinity to TcA.

The second prerequisite for successful transport is a net positive charge of the cargo protein. All naturally occurring HVRS of *P. luminescens* Tc toxins have a pI of at least 7.9 (TccC3HVR), and the protein with the lowest pI for which we observed translocation in our in vitro assay is HVR128-ILOV with a pI = 8.73 (Fig. 4). Since the gatekeeper constriction site that serves as the entry point into the TcA channel is formed by several acidic residues, negatively charged constructs might be repelled. In addition, the translocation channel of TcB has several negatively charged bands that facilitate the transport of cations but not anions. It is unlikely that the translocation behavior is different when the cargo is translocated across a native membrane in comparison with the in vitro system, as TcA forms a translocation channel through the membrane that is laterally closed and does not allow the entry of lipids into the channel lumen. The transport of the native TccC3HVR across lipid nanodiscs occurs without the need for a proton gradient or a chaperone, although a facilitation of translocation by the latter two factors cannot be excluded in the context of a cellular environment. Furthermore, single channel conductivity experiments and cell toxicity assays with TcA in the absence of a TcB-TcC cocoon show that an open pore is formed in the membrane. Consequently, we believe cargo proteins can move unhindered through the transmembrane channel provided their pI is basic enough to do so.

A sufficiently large size and a positive net charge are however not the only points that need to be considered, because some of the larger cargos with high pI were not translocated (TEV and HVR45-Cdc42-HVR50). Therefore, a third prerequisite needs to be fulfilled: the encapsulated cargo must not form any tertiary structures or stably interact with the cocoon. The two above-mentioned cargos violate this prerequisite, with TEV containing two highly stable β-barrels, and Cdc42 possessing an amphipathic C-terminus that associates with a hydrophobic binding pocket in the cocoon.

To summarize, we recommend adhering to the following guidelines in order to successfully turn a Tc toxin into a protein translocation device (Fig. 6): (i) Choose a protein between 20 and 35 kDa to insert after the autoproteolytic cleavage site of TcC. In case the cargo is too small, add N- or C-terminal extensions that do not interfere with protein function or link several copies of the protein together. (ii) Choose a protein with a pI of at least 8.0. Increase the pI by addition of positively charged residues or site-directed mutagenesis if necessary and possible. (iii) Avoid cargo proteins that might form highly stable structures already in the cocoon lumen. (iv) Avoid cargo proteins that contain amphipathic helices or extensive hydrophobic patches that might stably interact with the inner surface of the cocoon.

**Methods**

**Source plasmids for cargo proteins.** pGEX-ILOV was a gift from John Christie (Addgene plasmid #26587), pCDx3A-AN44-ICP47 containing the coding sequence (CDS) for ICP47 with a C-terminal HA epitope was a gift from Robert Tampé, Goethe University of Frankfurt, Germany. pGEX-RBD with the CDS for the Ras-binding domain (RBD) of CRAF kinase was a gift from Andreas Ernst, Goethe University of Frankfurt, Germany. A customized plasmid with the CDS for dihydrofolate reductase (DHFR) was a gift from Yaowen Wu, Max Planck Institute of Molecular Physiology, Dortmund, Germany. pOPIN-MBP-TEV with the CDS for TEV protease with a C-terminal penta-arginine tail was a gift from the Dortmund Protein Facility (DPF), Max Planck Institute of Molecular Physiology, Dortmund, Germany.

**Cloning of TcB-TcC with non-natural cargo proteins.** We used the fusion protein TcdB2-TccC10 as a carrier for heterologous cargo proteins to replace TccC3HVR. We therefore introduced an EcoRI restriction site by site-directed mutagenesis after the codon coding for the conserved P680 of TccC3, which is two residues after the aspartyl protease site. Subsequently, we cloned the cargo proteins in-frame via EcoRI and XhoI, resulting in an N-terminal extension of four residues (MPEF). In the case of TccC3HVR, the N-terminal extension results in a change of the pI from 8.73 to 7.90. In the case of Cdc42, the EcoRI site was inserted after the codon for
L678, and the resulting point mutation P680F was reverted by site-directed mutagenesis. Cargo proteins with N-terminal extensions were generated by inserting the EcoRI site 135 or 384 base pairs after the aspartyl protease site and restriction cloning as described above, resulting in 45 or 128 N-terminal residues of TccC3HVR and two residues (EF) encoded by the EcoRI site being attached to the cargo. Cargo proteins with C-terminal extensions were generated by inserting a NotI restriction site 150 base pairs upstream of the stop codon, followed by restriction cloning via EcoRI and NotI. This resulted in a C-terminal extension of the cargo proteins containing 50 C-terminal residues of TccC3HVR and three residues (GGGR) encoded by the NotI site. An overview of all resulting TcB-TcC cargos is listed in Fig. 4. An overview of the primers used in this study is shown in Supplementary Table 3.

Protein production. *P. luminescens* TcdA1 (TcA) was expressed and purified as described previously38. *E. coli* BL21-CodonPlus(DE3)-RIPL cells were transformed with pET19b containing the tcdA1 gene with an N-terminal hexahistidine tag and a pRex culture was inoculated from a freshly transformed colony. 10 L LB medium was inoculated to an OD600 of 0.05 and incubated at 37 °C. At an OD600 of 0.6, expression was induced by 25 µM IPTG and carried out overnight at 20 °C. Cells were then disrupted in a French pressure cell at 20,000 psi, 200 mM NaCl, 5 mM imidazole, 0.05% (v/v) Triton X-200. After centrifugation, eluate was loaded on a 5 mL NiNTA column and the supernatant was used as negative control. After washing with 10 CVs of washing buffer (20 mM Tris-HCl pH 8.0, 200 mM NaCl, 5 mM imidazole) and elution with 30 µM IPTG, the protein was eluted with 300 mM NaCl, 5% glycerol (using a microfluidizer). After removal of cell debris by centrifugation, the supernatant was applied to a 5 mL NiNTA column (GE Healthcare Life Sciences) and washed with 10 column volumes (CVs) of washing buffer (lysis buffer with 40 mM imidazole). Subsequently, the protein was eluted with elution buffer (20 mM Tris-HCl pH 8.0, 300 mM NaCl, 10% glycerol) using a microfluidizer. After removal of cell debris by centrifugation, the supernatant was applied to a 5 mL NiNTA column (GE Healthcare Life Sciences) and washed with 10 CVs of washing buffer (20 mM Tris-HCl pH 8.0, 200 mM NaCl, 5% glycerol), the protein was eluted with a linear gradient from 20 to 500 mM NaCl over 20 CVs. Fractions containing TcB-TcC were subjected to SEC using a Superdex 200 10/300 or a Superdex 200 16/60 column (GE Healthcare Life Sciences) equilibrated with 20 mM Tris-HCl pH 8.0, 150 mM NaCl, 5% glycerol as a final purification step. After washing with 10 CVs of washing buffer 2 (20 mM Tris-HCl pH 8.0, 20 mM NaCl, 5% glycerol), the protein was eluted with a linear gradient from 20 to 500 mM NaCl over 20 CVs. Fractions containing TcB-TcC were subjected to SEC using a Superdex 200 10/300 or a Superdex 200 16/60 column (GE Healthcare Life Sciences) equilibrated in gel filtration buffer (20 mM Tris-HCl pH 8.0, 150 mM NaCl, 5% glycerol) as a final purification step.

The gene coding for TccC3HVR (TccC(679–960)) was cloned in pET19b in frame with the TcC3HVR protease cleavage site and a hexahistidine tag. Expression was performed in *E. coli* BL21-CodonPlus(DE3)-RIPL cells. 2 L LB medium was inoculated to an OD600 of 0.05 from an overnight pre-culture and incubated at 37 °C. At an OD600 of 0.6, expression was induced by 25 µM IPTG and carried out overnight at 20 °C. Cells were then disrupted in a French pressure cell at 20,000 psi, 200 mM NaCl, 5 mM imidazole, 0.05% (v/v) Triton X-200. After centrifugation, eluate was loaded on a 5 mL NiNTA column (GE Healthcare Life Sciences) and washed with 10 CVs of washing buffer (20 mM Tris-HCl pH 8.0, 200 mM NaCl, 5 mM imidazole) and elution with 30 µM IPTG, the protein was eluted with elution buffer (20 mM Tris-HCl pH 8.0, 300 mM NaCl, 10% glycerol) using a microfluidizer. After removal of cell debris by centrifugation, the supernatant was applied to a 5 mL NiNTA column (GE Healthcare Life Sciences) and washed with 10 CVs of washing buffer (20 mM Tris-HCl pH 8.0, 200 mM NaCl, 5% glycerol), the protein was eluted with a linear gradient from 20 to 500 mM NaCl over 20 CVs. Fractions containing TcB-TcC were subjected to SEC using a Superdex 200 10/300 or a Superdex 200 16/60 column (GE Healthcare Life Sciences) equilibrated with 20 mM Tris-HCl pH 8.0, 150 mM NaCl, 5% glycerol) as a final purification step.

ABC holotoxin formation. Purified TcA (600 nM pentamer) and different TcB-TcC variants (1.2 µM) were mixed together and incubated for at least 1 h at 4 °C before removing the excess of free TcB-TcC by SEC on a Superose 6 Increase 5/150 column (GE Healthcare Life Sciences). For in vitro ADP-ribosylation, rabbit muscle actin was prepared as described previously39 and filamentous actin (F-actin) was formed by overnight incubation in ADP-ribosylation buffer (20 mM CAPS-NaOH pH 7.3 100 mM KCl, 2 mM MgCl2) at 4 °C. In total, 2 µl of F-actin were mixed with 1 µM NAD+ and different concentrations (50–500 µM) of recombinitely purified or translocated TccC3HVR and incubated for 12 min at 22 °C. The reaction was stopped by addition of SDS-PAGE sample buffer and immediate heating to 95 °C. ADP-ribosylation of F-actin was assessed via SDS-PAGE. For in vitro ADP-ribosylation, rabbit muscle actin was prepared as described previously39 and filamentous actin (F-actin) was formed by overnight incubation in ADP-ribosylation buffer (20 mM CAPS-NaOH pH 7.3 100 mM KCl, 2 mM MgCl2) at 4 °C. In total, 2 µl of F-actin were mixed with 1 µM NAD+ and different concentrations (50–500 µM) of recombinitely purified or translocated TccC3HVR and incubated for 12 min at 22 °C. The reaction was stopped by addition of SDS-PAGE sample buffer and immediate heating to 95 °C. ADP-ribosylation of F-actin was assessed via SDS-PAGE. Western blot and immunodetection using anti-p21-PAF ribose binding reagent (Millipore, Cat. No. MABE1016) at 1:2000 dilution and an HRP-conjugated goat anti-rabbit antibody (Bio-Rad, Cat. No. 170–6515) was applied as the secondary antibody in a 1:2000 dilution in all cases. Detection was performed with Western Lightning Plus ECL reagent (PerkinElmer, Cat. No. NEL104010E1A) and imaged in a ChemiDoc MP imaging system (Bio-Rad).

Isolation of translocated TccC3HVR. To isolate translocated TccC3HVR, we assembled ABC wild-type holotoxin (700 nM) as described above, and triggered the prepore-to-pore transition by dialysis against 20 mM CAPS-NaOH pH 11.2, 150 mM NaCl in the presence of 9 µM Msp1D1 nanodisc scaffold protein (Cubicle Biotech, Cat. No. 26112) and 490 µM 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (Avanti Polar Lipids, Cat. No. 850437) dissolved in 15% sodium cholate. After 72 h of dialysis at 4 °C, we subjected the holotoxin to SEC on a Superose 6 increase 5/150 column equilibrated in dialysis buffer and collected the fractions after the holotoxin peak (see Supplementary Fig. 3a).

ADP-ribosylation assay. For in vitro ADP-ribosylation, rabbit muscle actin was prepared as described previously39 and filamentous actin (F-actin) was formed by overnight incubation in ADP-ribosylation buffer (20 mM CAPS-NaOH pH 7.3 100 mM KCl, 2 mM MgCl2) at 4 °C. In total, 2 µl of F-actin were mixed with 1 µM NAD+ and different concentrations (50–500 µM) of recombinitely purified or translocated TccC3HVR and incubated for 12 min at 22 °C. The reaction was stopped by addition of SDS-PAGE sample buffer and immediate heating to 95 °C. ADP-ribosylation of F-actin was assessed via SDS-PAGE. Western blot and immunodetection using anti-p21-PAF ribose binding reagent (Millipore, Cat. No. MABE1016) at 1:2000 dilution and an HRP-conjugated goat anti-rabbit antibody as described above.

Fluorescence spectroscopy. Fluorescence emission spectra of TcB-TcC (WT), TcB-TcC-IOV and TcB-TcC-HVR130D-IOV (500 nm protein concentration) were recorded in 20 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.05% Tween-20 using a FluoroMax-4 fluorescence spectrophotometer (Horiba). The excitation wavelength was 430 nm and emission was recorded from 499 to 620 nm. Purified IOV with a GST-tag29 was used as positive control.

X-ray crystallography of TcB-TcC-Cdc42 and TcB-TcC-Cdc42. TcB-TcC-Cdc42 and TcB-TcC-TEV were crystallized using the sitting-drop vapor diffusion method and Western blot and immunodetection using anti-p21-PAF ribose binding reagent (Millipore, Cat. No. MABE1016) at 1:2000 dilution and an HRP-conjugated goat anti-rabbit antibody as described above.
at 20 °C. For TcB-TcC-Cdc42, initially, 2D crystals formed after mixing 1 µL of 10 mg/mL protein solution with 1 µL reservoir solution containing 0.1 M sodium chloride, 0.1 M magnesium chloride, 0.1 M tri-sodium citrate pH 5.5 and 5% PEG 4000. The 2D crystals were used to prepare a seed solution. Final 3D crystals were obtained by mixing 1 µL of 10 mg/mL protein solution with 0.5 µL seed solution and 1.5 µL reservoir solution containing 0.1 M magnesium chloride, 0.1 M tri-sodium acetate pH 4.6 and 12% PEG 6000. TcB-TcC-TEV crystallized in the same crystallization buffer by sitting overnight. Prior to flash freezing in liquid nitrogen, the crystals were soaked in reservoir solution containing 20% glycerol as a cryoprotectant.

X-ray diffraction data were collected at the PXII-X10SA beamline at the Swiss Light Source (Villigen, Switzerland) using a wavelength of 0.97958 Å and 0.9998 Å for TcB-TcC-Cdc42 and TcB-TcC-TEV, respectively. The X-ray data set was integrated and scaled using XDS45. Phases were determined by molecular replacement with PHASER implemented in PHENIX46 using the crystal structure of WT TcB-TcC-TcC3 (PDB 4O9X) as a search model. PHASER was executed with a pixel size of 7.2 Å/pixel on the unit cell dimensions of 96 x 156 x 179 Å and one molecule per asymmetric unit. TcB-TcC-TEV crystallized in the orthorhombic space group P212121 with unit cell dimensions of 234 x 234 x 143 Å at a cryo-temperature of 100 K. The final density was estimated to be 7.02/5.11 Å3/Å2.

**References**

1. Waterfield, N. R., Bowen, D. J., Fetherston, J. D., Perry, R. D. & ffrench-Constant, R. H. The tc genes of Photorhabdus: a growing family. Trends Microbiol. 9, 185–191 (2001).

2. ffrench-Constant, R. & Waterfield, N. An ABC guide to the bacterial toxin complexes. Advances in Applied Microbiology 58, 169–183 (Elsevier, 2005).

3. Bowen, D. et al. Insecticidal toxins from the bacterium Photorhabdus luminescens. Science 280, 2289–2292 (1998).

4. Sergeant, M., Jarrett, P., Ousley, M. & Morgan, J. A. W. Interactions of insecticidal toxin gene products from Xenorhabdus nematophagus PMF296. Appl. Environ. Microbiol. 69, 3344–3349 (2003).

5. ffrench-Constant, R. H. & Bowen, D. J. Novel insecticidal toxins from nematode-symbiotic bacteria. Cell Mol. Life Sci. 57, 828–833 (2000).

6. Gerrard, J., Waterfield, N., Vohra, R. & ffrench-Constant, R. Human infection with Photorhabdus asymbiotica: an emerging bacterial pathogen. Microbes Infect. 6, 229–237 (2004).

7. Tennant, S. M., Skinner, N. A., Joe, A. & Robins-Browne, R. M. Homologues of insecticidal toxin complex genes in Yersinia enterocolitica biotype 1A and their contribution to virulence. Infect. Immun. 73, 6860–6867 (2005).

8. Waterfield, N., Hares, M., Huchfifie, S., Wren, B. & ffrench-Constant, R. The insect toxin complex of Yersinia. Adv. Exp. Med. Biol. 603, 247–257 (2007).

9. Gatoufos, C. et al. A syringe-like injection mechanism in Photorhabdus luminescens toxins. Nature 495, 520–523 (2013).

10. Meusch, D. et al. Mechanism of Tc toxin action revealed in molecular detail. Nature 508, 61–65 (2014).

11. Gatoufos, C. et al. Membrane insertion of a Tc toxin in near-atomic detail. Nat. Struct. Mol. Biol. 23, 884–890 (2016).

12. Busby, J. N. et al. Structural analysis of Chi1 Chitinase from Yen-Tc: the multisubunit insecticidal ABC toxin complex of Yersinia enterocolitica. J. Mol. Biol. 415, 359–371 (2012).

13. Piper, S. J. et al. Cryo-EM structures of the pore-forming A subunit from the Yersinia enterocolitica ABC toxin. Nat. Commun. 10, 1952 (2019).

14. Busby, J. N., Panjikar, S., Landsberg, M. J., Hurst, M. R. H. & Lott, J. S. The BC component of ABC toxins is an RHS-repeat-containing protein encapsulation device. Nature 501, 547–550 (2013).

15. Roderer, D., Hofnegel, O., Benz, R. & Rauner, S. Structure of a Tc holotoxin pore provides insights into the translocation mechanism. https://www.pnas.org/content/early/2019/12/09/1909821116 (2019).

16. Gatoufos, C. et al. Tc toxin activation requires unfolding and refolding of B-propeller. Nature 563, 209–213 (2018).

17. Roderer, D. & Rauner, S. Tc toxin complexes: assembly, membrane permeation, and protein translocation. Annu. Rev. Microbiol. 73, 247–265 (2019).

18. Lang, A. E. et al. Photorhabdus luminescens toxins ADP-ribosylate actin and RhoA to force actin clustering. Structure 327, 1139–1142 (2010).

19. Leidreiter, F. et al. Common architecture of Tc toxins from human and insect pathogenic bacteria. Sci. Adv. 5, eaax6497 (2019).

20. Han, S., Arvai, A. S., Clancy, S. B. & Tainer, J. A. Crystal structure and novel recognition motif of rho ADP-ribosylating C3 exoenzyme from Clostridium botulinum: structural insights for recognition specificity and catalysis. J. Mol. Biol. 305, 95–101 (2001).

21. Schleberger, C., Hochmann, H., Barth, H., Aktories, K. & Schulz, G. E. Structure and action of the binary C2 toxin from Clostridium botulinum. J. Mol. Biol. 364, 705–715 (2006).

22. O'Neil, C. J., Jobling, M. A., Holmes, R. K. & Hol, W. G. J. Structural basis for the activation of cholera toxin by human ARF6-GTP. Science 309, 1093–1096 (2005).

23. Tsumura, T. et al. Arginine ADP-ribosylation mechanism based on structural snapshots of iota-toxin and actin complex. Proc. Natl. Acad. Sci. USA 110, 4267–4272 (2013).

24. Zahaf, N.-I. et al. Targeted delivery of an ADP-ribosylating bacterial toxin into cancer cells. Sci. Rep. 7, 41252 (2017).

25. Kiyokawa, T. et al. Cytotoxicity of interleukin 2 toxin toward lymphocytes from patients with adult T-cell leukemia. Cancer Res. 49, 4042–4046 (1989).

26. Kreitzman, R. J., Siegall, C. B., Chaudhary, V. K., FitzGerald, D. J. & Pastan, I. Properties of chimeric toxins with two recognition domains: interleukin 6 and transforming growth factor alpha at different locations in Pseudomonas aeruginosa. Bioconjug. Chem. 3, 63–68 (1992).

27. Kühn, S. et al. The structure of the FMN12-Cdc42 yields insights into the mechanism of lamellipodia and filopodia formation. Nat. Commun. 6, 7088 (2015).

28. Pfländer, R. et al. Structure of the active domain of the herpes simplex virus protein ICP47 in water/sodium dodecyl sulfate solution determined by nuclear magnetic resonance spectroscopy. Biochemistry 38, 13692–13698 (1999).

29. Chapman, S. et al. The photoreversible fluorescent protein iLOV outperforms GFP as a reporter of plant virus infection. Proc. Natl. Acad. Sci. USA 105, 20038–20043 (2008).

30. Cao, H. & Skolnick, J. Time-resolved x-ray crystallography capture of a slow reaction tetrahydrofuran intermediate. Struct. Dyn. 6, 024701 (2019).
Acknowledgements

We thank K. Vogel-Bachmayr for excellent technical support, and O. Hofnagel and D. Prumbaum for assistance with EM. We thank R. Tampé for a plasmid containing the ICP47 sequence and A. Ernst for a plasmid containing the RBD sequence. This work was supported by funding from the Max Planck Society (to S.R.) and the European Research Council under the European Union’s Seventh Framework Programme (FP7/2007–2013 grant no. 615984, to S.R.).

Author contributions

S.R. designed and supervised the project. D.R. designed proteins. D.R. performed the assembly and translocation experiments. D.R. and O.S. performed fluorescence spectroscopy. E.S. crystallized TcB-TcC-Cdc42 and TcB-TcC-TEV, and solved the crystal structures. D.R. processed and analyzed cryo-EM data of ABC-Cdc42. D.R., O.S., and S.R. wrote the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information is available for this paper at https://doi.org/10.1038/s41467-019-13253-8.

Correspondence and requests for materials should be addressed to S.R.

Peer review information Nature Communications thanks Shaun Lott and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019